|
Daily Medical Update
Cancer Screening: Lung (LDCT eligibility)
Wednesday, February 25, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
JAMA Internal Medicine (2025) - Randomized Clinical Trial
Key Findings
- At 3 months, self-reported abstinence was 37.1% with integrated care vs 25.2% with quitline and 27.1% with quitline-plus.
- Higher counseling exposure inside the screening environment was associated with better quit outcomes than referral-centric models.
📋 Practice Implication: Treat LDCT referral as a same-episode trigger for in-program tobacco treatment enrollment, not a separate downstream quitline handoff.
|
JAMA Internal Medicine (2025) - Factorial Randomized Controlled Trial
Key Findings
- Six-month 7-day abstinence improved with 8 counseling sessions vs 4 (17.3% vs 11.7%; risk difference 5.6%, 95% CI 0.1-11.0).
- Abstinence showed no significant difference by NRT duration (8 vs 2 weeks) or by SDOH-screening referral vs no referral in this factorial analysis.
📋 Practice Implication: When resources are limited, prioritize delivering a full counseling course before expanding NRT duration or adding non-core workflow elements.
|
Lung Cancer (2025) - Randomized Controlled Trial
Key Findings
- Biochemically verified 7-day abstinence was higher with digital support at 3 months (35.1% vs 15.4%) and 6 months (24.3% vs 10.3%).
- LDCT adoption at 6 months nearly doubled in the digital arm (58.1% vs 29.5%).
📋 Practice Implication: For patients missing or delaying scans, deploy digital decision-aid plus cessation bundles as an outreach strategy to increase completed screening.
|
JAMA Network Open (2026) - Economic Evaluation of RCT
Key Findings
- Health-system analysis of Screen ASSIST strategies found improved quit outcomes with acceptable incremental cost-per-quit across intervention combinations.
- Results favor structured integrated treatment over usual-care minimal referral from a value perspective.
📋 Practice Implication: Use cost-effectiveness evidence to support payer or system-level business cases for embedded tobacco-treatment staffing in LCS pathways.
|
Acta Oncologica (2025) - Prospective Randomized Trial
Key Findings
- Across two rounds, LDCT uptake was 96.7%; six cancers were found with a positive predictive value of 75%.
- Stage distribution shifted toward earlier disease, with 83% (5/6) of detected cancers at stage I and treated with curative intent.
📋 Practice Implication: Build centralized invitation/reminder logistics and closed-loop follow-up to maximize completion rates and early-stage detection in eligible smokers.
|
|
Recent randomized evidence suggests the biggest practice lever in lung cancer screening is integrating high-intensity tobacco treatment directly into LDCT workflows. Digital multicomponent programs can improve both smoking abstinence and screening uptake, while implementation data highlight equity-sensitive barriers to participation. For PCPs, eligibility conversations should pair LDCT referral with immediate cessation pathways rather than delayed external referral-only models.
|
|